Related Experiment Video
Updated: Aug 8, 2026

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Specificity of certain biochemical derangements in hepatocarcinogenesis
Abstract:
Earlier work on acid-soluble nucleotides and other liver constituents as affected by azo-dye carcinogenesis has now been extended, with trial of ethionine (weakly carcinogenic) and of α-naphthylisothiocyanate (noncarcinogenic). The effects of ethionine feeding on whole-tissue nucleotide levels were not dramatic, and were generally dissimilar to those produced by azo-dye feeding. However a fall in some or all of the purine nucleotides can still be regarded as a feature of hepatocarcinogenesis.A fall in mitochondrial nucleotides, as previously found in azo-dye experiments, likewise occurs with ethionine feeding, but also with α-naphthylisothiocyanate. It is suggested that the latter warrants testing as a co-carcinogen. Unlike azo-dyes, ethionine is without adverse effect on the yield of protein in cytoplasmic particles and (in common with α-naphthylisothiocyanate) it raises the yield of RNA in the supernatant fraction.In liver from ethionine-fed rats and in ethionine-induced hepatomas, the activity of enzymes concerned in UMP synthesis showed a rise more striking than that found with azo-dyes.
More Related Videos
08:40A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
Published on: August 7, 2020
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mutagenicity and Carcinogenicity
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Bioactivation and Tissue Toxicity